Mentatcurated
Longevity & Health medium · independent

The marker moved, the arteries didn't

Novo Nordisk's ziltivekimab suppressed the blood markers of inflammation exactly as designed and then prevented no heart attacks, strokes or cardiac deaths across more than 6,300 high-risk patients.

The number came back 0.99. Across more than 6,300 patients with narrowed arteries, failing kidneys and inflammation showing in their blood, Novo Nordisk's antibody ziltivekimab produced a rate of heart attacks, strokes and cardiac deaths one percent below placebo, which in a trial this size means no difference at all. The drug was not inert. It blocks interleukin-6, one of the immune system's main inflammation signals, and the inflammatory markers in patients' blood fell exactly as far as the earlier studies promised.

IL-6 is also how the body fights infection. Patients on the drug had more serious infections, and got nothing back for them.

Cardiology had good reason to expect better. In 2017 a trial called CANTOS showed that quieting inflammation cut heart attacks in people who had already had one, independent of cholesterol, and the field has chased that target ever since. Ziltivekimab looked like the cleaner shot: in mid-stage testing it pushed the standard inflammation blood test down by up to 92 percent, against roughly 37 percent for the CANTOS drug. Human genetics pointed the same way, since people who inherit variants that naturally quiet IL-6 signalling for life get less heart disease, which is about as close to a natural experiment as medicine gets. Twice the biochemical effect, with genetics as a tailwind, and the events did not move.

Two explanations are live, and they blame different things. One is that the trial recruited the wrong patients: everyone enrolled had advanced kidney disease, which raises inflammation readings for its own reasons, so the blood test may have been reporting on failing kidneys rather than on inflamed artery walls. The other is that the drug grabbed the wrong rung of the pathway, blocking the IL-6 molecule itself where the genetic evidence runs through the receptor it docks into. Both carry the same warning about the test. hs-CRP is measured in millions of routine blood panels as a stand-in for cardiac risk, and in these patients it was driven nearly to the floor without the risk following it down.

The full results are not published yet; this is a top-line company announcement, with the detail due at a scientific meeting later this year. Two more ziltivekimab outcome trials are still running, one in heart failure and one in people just after a heart attack, both reading out in the first half of 2027. Those are now the experiment that decides whether ZEUS picked the wrong patients or the field picked the wrong molecule.

The lenses

Novelty 4
Impact · breadth 3
Impact · depth 4
Actionable 1
Delight 3
Substance 3
Hype 3

The facts

DrugZiltivekimab, a monthly injected antibody that blocks interleukin-6
TrialZEUS: over 6,300 patients with artery disease, chronic kidney disease and raised inflammation
ResultHazard ratio 0.99 (95% CI 0.88 to 1.11): no effect on heart attacks, strokes or cardiac death
StatusTop-line company announcement, 31 July 2026; full data due at a meeting later in 2026, not yet peer reviewed
Open erictopol.substack.com →

How this connects

Tap a node to open it

How this connects